Core Viewpoint - The stock of Gilead Sciences-B (01672) opened down over 9% and is currently trading at 16.5 HKD, with a transaction volume of 868 million HKD due to a significant share sale and subscription announcement by its controlling shareholder [1] Group 1: Shareholder Actions - The controlling shareholder, JJW12 Limited, will sell 52.4 million shares, representing approximately 5.44% of the company's existing issued share capital [1] - JJW12 Limited will also subscribe to 28.82 million new shares, accounting for about 2.9% of the enlarged share capital, at a price of 16.45 HKD per share, which is a 9.9% discount to the closing price on August 18 [1] Group 2: Fund Utilization - The net proceeds from the fundraising are approximately 468 million HKD, with around 90% allocated for clinical trial research and development related to subcutaneous and oral peptide candidates for obesity treatment, and the remaining 10% for working capital and general corporate purposes [1] Group 3: Shareholding Changes - Following the transactions, JJW12 Limited's shareholding will decrease from approximately 53.38% to 49.45%, while the total shareholding of the controlling shareholder will drop from 62.21% to 58.03% [1]
歌礼制药-B低开逾9% 折让9.9%先旧后新配股 净筹4.68亿港元